Masimo Corporation (NASDAQ:MASI) Shares Acquired by Calamos Advisors LLC

Calamos Advisors LLC boosted its position in shares of Masimo Corporation (NASDAQ:MASI - Free Report) by 44.0% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 23,449 shares of the medical equipment provider's stock after purchasing an additional 7,169 shares during the quarter. Calamos Advisors LLC's holdings in Masimo were worth $3,907,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Jones Financial Companies Lllp purchased a new stake in Masimo during the fourth quarter worth $27,000. Farther Finance Advisors LLC raised its holdings in shares of Masimo by 128.9% in the first quarter. Farther Finance Advisors LLC now owns 206 shares of the medical equipment provider's stock worth $35,000 after acquiring an additional 116 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Masimo by 40.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock worth $37,000 after acquiring an additional 64 shares during the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of Masimo by 31.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider's stock worth $42,000 after acquiring an additional 60 shares during the last quarter. Finally, SBI Securities Co. Ltd. acquired a new position in shares of Masimo in the fourth quarter worth $46,000. 85.96% of the stock is currently owned by hedge funds and other institutional investors.

Masimo Trading Down 2.1%

NASDAQ:MASI traded down $3.67 on Friday, hitting $167.67. 498,674 shares of the stock were exchanged, compared to its average volume of 639,289. The stock has a market cap of $9.09 billion, a PE ratio of -18.28 and a beta of 1.19. The company has a current ratio of 2.17, a quick ratio of 1.62 and a debt-to-equity ratio of 0.67. The stock has a fifty day moving average of $161.89 and a 200-day moving average of $166.46. Masimo Corporation has a fifty-two week low of $101.61 and a fifty-two week high of $194.88.

Masimo (NASDAQ:MASI - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 EPS for the quarter, topping the consensus estimate of $1.24 by $0.12. The company had revenue of $372.00 million during the quarter, compared to analyst estimates of $367.79 million. Masimo had a positive return on equity of 22.56% and a negative net margin of 25.06%. The firm's revenue was down 24.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.77 earnings per share. As a group, equities analysts expect that Masimo Corporation will post 4.1 earnings per share for the current fiscal year.

Insider Activity

In other news, COO Bilal Muhsin sold 10,000 shares of the stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $163.28, for a total value of $1,632,800.00. Following the completion of the sale, the chief operating officer owned 24,172 shares in the company, valued at approximately $3,946,804.16. This trade represents a 29.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 9.70% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. BTIG Research set a $193.00 price target on Masimo and gave the stock a "buy" rating in a report on Wednesday, May 7th. Piper Sandler reissued an "overweight" rating and issued a $200.00 price target (down from $215.00) on shares of Masimo in a report on Wednesday, May 7th. Raymond James Financial cut their price target on Masimo from $204.00 to $185.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Needham & Company LLC reissued a "hold" rating on shares of Masimo in a report on Thursday, April 10th. Finally, Wall Street Zen cut Masimo from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, Masimo presently has an average rating of "Moderate Buy" and a consensus price target of $191.60.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.